488798-38-5

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 

Downstream Products

• 1207460-23-8 (2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidin-5-yl)methanol 
• 1218994-93-4 (4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidine-5-yl)methanol 
• 1218994-94-5 4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidine-5-carbaldehyde 
• 1218994-92-3 methyl (4-(4-fluorophenyl)-6-isopropyl-2-(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidine-5-carboxylate 
• 147118-36-3 N-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-(propan-2-yl)pyrimidin-2-yl]-N-methylmethanesulfonamide 
• 160009-36-9 methyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylamino)pyrimidine-5-carboxylate 
• 289042-11-1 methyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methanesulphonyl-N-methylamino)pyrimidine-5-carboxylate 
• 1263475-93-9 4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl(methyl)amino)pyrimidine-5-carboxylic acid 

Relevant academic research and scientific papers

Quantum Chemical Calculations (Ab Initio & DFT), Hirshfeld Surface Analysis, Crystal Structure and Molecular Docking Study of 2-Chloro-4-(4-fluoro-phenyl)-6-isopropyl-pyrimidine-5-carboxylic Acid Methyl Ester

Abstract: Pyrimidine derivatives are well-known nitrogen containing heterocyclic compound which play an important role in medicinal and pharmaceutical applications. The synthesized compound, 2-chloro-4-(4-fluoro-phenyl)-6-isopropyl-pyrimidine-5-carboxylic

Facile synthesis of (E)-5-styrylpyrimidines via wittig reaction using sodium tripolyphosphate in water

An inexpensive and eco-friendly Wittig olefination protocol has been developed to pre-pare novel (E)-5-styrylpyrimidines. The reaction of pyrimidine phosphonium ylide with different aryl/heteroaryl aldehydes underwent smoothly in the presence of sodium tr

Efficient Construction of the Nucleus of Rosuvastatin Calcium

A novel and efficient five-step synthetic route, including a Biginelli reaction, dehydrogenation, chlorination, sulfonamidation, and reduction, for the core of Rosuvastatin was established. All steps were systematically studied. Tert-butylhydroperoxide aqueous solution was applied in the dehydrogenation instead of nitric acid. N,N-dimethylaniline was employed as a catalyst to accelerate the chlorination proceeding smoothly, and its catalytic mechanism is discussed. In the sulfonamidation, the conversion of compound 5 was obviously improved by use of NaH and acetonitrile. In addition, two sulfonamidation side products 6 and 7 were detected and isolated. Thus, under the optimized reaction conditions, the target product was obtained in 60.4% total yield, much higher than the reported yield (36.4%).

A PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES

The present invention relates to an improved process for synthesizing calcium salt of (E)-7-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid (Rosuvastatin Calcium) in high purity.